In the first nine months of 2025, Tempus AI Inc. TEM achieved several key regulatory milestones that strengthened its position in AI-driven diagnostics. In September 2025, the company received FDA 510 ...

UPPSALA, SE / ACCESS Newswire / June 30, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, ...

Tempus AI (TEM) may be building one of healthcare's fastest-growing artificial intelligence (AI) platforms, but the stock ...

Tempus AI TEM is slowly becoming one of the most vertically integrated data and diagnostics platforms in healthcare, bringing together genomics, multimodal real-world data and clinical AI into a ...

Tempus AI Inc (NASDAQ:TEM) is one of the 12 Best Mid-Cap AI Stocks to Buy According to Analysts. On May 29, Tempus AI Inc (NASDAQ:TEM) announced that it had received FDA approval for a tumor-only ...

I'm David Westenberg, the life science tools and diagnostics analyst at Piper. With me today is Tempus AI. I'm happy to have the CFO, Jim Rogers. Liz is in the audience as well, if anyone -- any ...

Investors with a lot of money to spend have taken a bullish stance on Tempus AI (NASDAQ:TEM). And retail traders should know. We noticed this today when the trades showed up on publicly available ...

Artificial Intelligence (AI)-based healthcare solutions company Tempus AI TEM has continued to capture investors’ attention despite reporting weaker-than-expected fourth-quarter 2024 results on Feb.

Deep-pocketed investors have adopted a bearish approach towards Tempus AI (NASDAQ:TEM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...

Tempus AI TEM is slated to release fourth-quarter 2025 results on Feb. 24, after market close. During the quarter, the company advanced several strategic collaborations and product innovations that ...